
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. is poised for significant future growth, supported by a projected improvement in its legacy Performance Suite Medical Expense Ratio (MER) by 500 basis points, reaching 89%. The company's robust growth strategy includes cross-selling new services and upselling risk-based products, coupled with the expectation of strong top-line growth through increased contract acquisitions and improved margins, targeting a $150 million EBITDA run-rate by the end of 2026. Furthermore, the anticipated sequential EBITDA increases in the upcoming quarters, amounting to $32.5 million in Q3 and $45 million in Q4, underscore the company's strong operational performance and optimism for continued financial success.
Bears say
Evolent Health Inc. is experiencing significant challenges, as evidenced by a projected revenue decline of approximately $100 million related to its legacy Performance Suite, leading to anticipated revenues of around $850 million for that segment. Furthermore, the company has lowered its earnings per share (EPS) estimates for 2026 and 2027 to $0.18 and $0.45, respectively, from previous estimates of $0.34 and $0.52, indicating worsening financial prospects. Additionally, although the company expects some cost reductions from efficiency initiatives, the overall outlook remains bleak, with flat sequential performance anticipated for the second quarter and ongoing declines in critical revenue streams.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares